LivaNova price target raised to $85 after strong Q2 results

Record quarterly revenue of $390.6 million and adjusted EPS of $1.26 topped expectations, supported by growth in the Cardiopulmonary and Epilepsy businesses.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.